Press Release Archive

 
07.09.2020 -   Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
*/ /*-->*/ /*-->*/
  • Funding to Support Development of New Antibiotics as Part of Broader Industry Effort
  • New Partnership with More than 20 Other Companies Will Focus on Medicines that Address Most Resistant Bacteria and Life-Threatening Infections
  • Builds on Pfizer’s longstanding work to address the global burden of infectious di
 
06.30.2020 - FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
  • First and only FDA-approved immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III study
  • In JAVELIN Bladder 100, BAVENCIO maintenance treatment extended median overall survival by 50% over standard of care
  • Priority review completed under FDA’s Real-Time Oncology Review (RTOR) pilot program, following receipt of Breakthrough Therapy Designation

Rockland, MA and New York, US, JUNE 30, 2020 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer In

 
06.30.2020 - European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

体育投注正规网址NEW YORK, N.Y., June 29, 2020 – Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved DAURISMO™ (glasdegib), a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy.

 
06.25.2020 - Pfizer Declares Third-Quarter 2020 Dividend
*/ /*-->*/ /*-->*/

Board of Directors approves quarterly cash dividend of $0.38 per share

 
06.24.2020 - Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
*/ /*-->*/ /*-->*/
  • Antimicrobial resistance is a leading global health challengei that requires urgent action to ensure a safer world for everyone, everywhere
  • Effective surveillance and timely data feedback are cri
 
06.22.2020 - European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

体育投注正规网址Darmstadt, Germany, and New York, US, June 22, 2020 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency (EMA) has validated for review the Type II variation application for BAVENCIO® (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC). With this validation, the application is complete, and the EMA will now begin the review procedure.

 
06.22.2020 - Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
*/ /*-->*/ /*-->*/

First subjects recently administered immunizations in two studies of 20-valent pneumococcal conjugate vaccine candidate in infants; a pentavalent meningococcal vaccine candidate in adolescents; and a respiratory syncytial virus vaccine candidate in

 
06.22.2020 - European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Notintendedfor UK-based media

Darmstadt, Germany, and New York, US, June 22, 2020 – Merck and Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency (EMA) has validated for review the Type II variation application for BAVENCIO® (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC). With this validation, the application is complete, and the EMA will now begin the review procedure.

 
06.18.2020 - Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
*/ /*-->*/ /*-->*/

体育投注正规网址 NEW YORK--(BUSINESS WIRE)-- Upjohn Inc. (“Newco”), a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”) (NYSE: PFE), Upjohn Finance B.V. (“Finco”), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V.

 
06.16.2020 - Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
*/ /*-->*/ /*-->*/

体育投注正规网址 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 28, 2020.

 
06.12.2020 - Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th
*/ /*-->*/ /*-->*/

体育投注正规网址 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Thursday, June 18, 2020 at 11:30 a.m. EDT.

 
06.11.2020 - FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
*/ /*-->*/ /*-->*/

体育投注正规网址 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.

 
06.10.2020 - Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
*/ /*-->*/ /*-->*/

-Observed improvements in skin clearance, disease extent, and severity among patients 12 to <18-

-Safety profile consistent with other pivotal studies of abrocitinib reported to date-

 
06.02.2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 1:20 p.m. EDT.

 
06.02.2020 - Pfizer Establishes New Program to Support Continued Biotechnology Innovation
*/ /*-->*/ /*-->*/

Pfizer Breakthrough Growth Initiative will invest up to $500 million across a portfolio of clinical-stage biotechnology companies

 
05.29.2020 - Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc.

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.